Gastrointestinal (GI) Stool Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The gastrointestinal (GI) stool testing market size in 2026 is estimated at USD 0.89 billion, growing from 2025 value of USD 0.83 billion with 2031 projections showing USD 1.24 billion, growing at 6.85% CAGR over 2026-2031. This report is Segmented by Product Type (Instrument and Consumables), Test Type (Occult Blood, Ova and Parasites, Bacteria Pathogens, and More), Technology (Immunoassay, Molecular PCR, and More), End User (Hospitals, Diagnostic Labs, Physician Offices, and More) and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Gastrointestinal (GI) Stool Testing Market Trends and Insights

Rising prevalence of GI disorders & CRC screening mandates

Lowering the US colorectal-cancer screening age to 45 instantly added 19 million eligible adults, swelling the overall screening cohort to 117.1 million. Medicare now reimburses multi-target stool DNA tests every three years for average-risk beneficiaries, eliminating out-of-pocket cost barriers when providers accept assignment. Community clinics saw a 22.9% jump in completed screenings after the guideline change, yet uptake among newly eligible 45-49-year-olds lags at 9.6%. Persistently low participation among Hispanic adults with limited English proficiency underscores the need for culturally adapted outreach tools. Exact Sciences reports its flagship Cologuard test has already detected 623,000 cancers and precancers, 80% at early stage, preventing an estimated USD 22 billion in downstream treatment costs.

Point-of-care FIT/iFOBT adoption surge

Immunochemical rapid tests remove dietary restrictions tied to traditional guaiac cards and deliver results within 10 minutes, enabling same-visit clinical decisions. FDA clearance of multiple CLIA-waived lateral-flow platforms, plus Medicare Local Coverage Determination L39226 supporting multiplex pathogen panels, has quickened placement in primary-care settings. The EU’s Regulation 2017/746 harmonizes device rules, though separate UKCA marking now applies post-Brexit. Health-economic studies show PCR-based point-of-care testing cuts unnecessary antibiotic days from 4 to 1, offsetting higher per-test costs through reduced drug use. Smartphone-connected devices such as Preventis QuantOn Cal transmit calprotectin results directly to clinicians and bolster chronic-disease monitoring.

High instrument & cartridge costs

Multiplex PCR analyzers cost USD 150,000-300,000 and entail consumables running USD 40-60 per assay, deterring uptake in budget-constrained systems. Cost modelling indicates stool DNA screening must fall from USD 350 to roughly USD 50 to equal annual fecal occult blood testing on cost-effectiveness metrics. Emerging-market laboratories report mean diagnostic prices of USD 2.62, underscoring extreme price sensitivity. Limited manufacturer competition and opaque procurement processes further elevate local pricing, while some private insurers classify broad fecal analysis panels as investigational and deny payment.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of molecular enteric-pathogen panels
• Growth of at-home collection & telehealth integration
• Stringent & varied regulatory approval timelines

Segment Analysis

Consumables generated 59.12% of sales in 2025 and are forecast to post a 7.32% CAGR, the quickest pace within the gastrointestinal (GI) stool testing market. Instruments accounted for the remaining revenue and will track a slower 6.68% advance as the installed base matures yet still requires routine updates. Recurring reagent purchases, high-tolerance collection tubes and single-use cartridges position consumables as the backbone of day-to-day testing workflows. Innovation such as BIOHIT’s FAEX Sample System tightens leak control and doubles as a dropper tube, reducing laboratory preprocessing steps and supporting premium price points despite budgetary scrutiny.

Ongoing guideline updates that expand eligible populations lift specimen volumes, ensuring strong pull-through for reagents, stabilizers and molecular cartridges. As labs automate extraction and amplification, high-margin consumables increasingly outpace capital equipment in total contribution to the gastrointestinal (GI) stool testing market size.

Occult blood tests held 40.75% of global revenue in 2025, anchored by widespread FIT reimbursement and physician familiarity. Viral pathogen panels, though smaller, are projected to grow at 7.26% CAGR, outstripping all other categories within the gastrointestinal (GI) stool testing market. Demand is fueled by norovirus- and rotavirus-driven outbreaks that require real-time containment, especially in long-term-care and food-service environments. Multiplex PCR assays identify co-infections rapidly and support precise isolation policies, giving hospitals a compelling ROI even at higher list prices.

Bacterial panels and ova-and-parasite assays continue to serve endemic regions and immunocompromised cohorts, but viral panels’ superior growth trajectory reflects heightened post-pandemic vigilance and willingness to pay for speed and comprehensiveness. These dynamics are expected to tilt incremental spending toward syndromic testing menus and to enlarge the overall gastrointestinal (GI) stool testing market size for infectious disease management.

Complete Report Scope:

• By Product Type
  • Instruments
  • Consumables
• By Test Type
  • Occult Blood
  • Ova & Parasites
  • Bacterial Pathogens
  • Viral Pathogens
  • Others
• By Technology
  • Immunoassay
  • Molecular PCR
  • Next-Generation Sequencing
  • Lateral Flow / Rapid Tests
• By End User
  • Hospitals
  • Diagnostic Labs
  • Physician Offices & POC Sites
  • Others
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained 39.08% of global revenue in 2025 on the back of expansive Medicare coverage, clear FDA pathways and high provider awareness. The region’s CRC screening mandates, strong payer mix and concentration of sophisticated laboratories keep test volumes high, contributing materially to the gastrointestinal (GI) stool testing market size. Yet Asia-Pacific is forecast for the swiftest 7.52% CAGR as Japan’s aging population, China’s broadened reimbursement basket and India’s infectious-disease burden converge with regulatory harmonization efforts to boost adoption of molecular panels. Local manufacturing incentives and value-priced platforms cater to cost-conscious purchasers, further accelerating uptake.

Europe, home to roughly 27.86% of revenue, benefits from consistent IVDR standards and robust public insurance coverage, though reimbursement differences among member states temper uniform roll-out. South America’s combined 20.62% share reflects steady public-health investment in screening and pathogen surveillance, while local currency volatility constrains premium platform imports. The Middle East and Africa hold about 12.44% share, with select Gulf Cooperation Council states tapping oil-backed budgets to fund molecular diagnostics, contrasted with low-income countries relying on donor support for FIT distribution. Rising GI disease awareness and decentralization of testing within emerging markets steadily close the adoption gap. Portable platforms and caravan-style screening campaigns demonstrate value where lab infrastructure is sparse, supporting incremental expansion of the gastrointestinal (GI) stool testing market.

List of Companies Covered in this Report:

• Abbott Laboratories
• Danaher Corp (Beckman Coulter)
• bioMérieux
• Quest Diagnostics
• Meridian Bioscience (SD Biosensor)
• Thermo Fisher Scientific
• Siemens Healthineers
• Bio-Rad Laboratories
• DiaSorin
• Becton Dickinson & Co.
• QuidelOrtho Corp.
• Epitope Diagnostics
• ScheBo Biotech
• CTK Biotech
• Genova Diagnostics
• Eurofins
• Randox Laboratories
• Roche
• Seegene
• Hologic
• Cardinal Health

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support